Produktname:5-Bromo-2-fluoro-1,3-dimethylbenzene

IUPAC Name:5-bromo-2-fluoro-1,3-dimethylbenzene

CAS:99725-44-7
Molekulare Formel:C8H8BrF
Reinheit:95%+
Katalognummer:CM256101
Molekulargewicht:203.05

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM256101-100g in stock ƞȀǕ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:99725-44-7
Molekulare Formel:C8H8BrF
Schmelzpunkt:-
SMILES-Code:CC1=CC(Br)=CC(C)=C1F
Dichte:
Katalognummer:CM256101
Molekulargewicht:203.05
Siedepunkt:205°C at 760 mmHg
Mdl-Nr.:MFCD01320701
Lagerung:Store at room temperature.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Orforglipron
Obesity is becoming an increasingly serious public health problem globally, plaguing millions of people and significantly increasing their risk of chronic diseases such as diabetes and heart disease. In recent years, with the approval of new weight loss drugs such as Wegovy (Semaglutide) and Mounjaro (Tirzepatide), people's attention to this field has once again heated up, spawning an upsurge in the research and development of new treatments. There are currently nearly 70 obesity treatments in the research and development stage. Eli Lilly's Orforglipron is the world's first oral small molecule GLP-1RA to start Phase III clinical trials.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products